Eclipsys at UBS Global Life Sciences Conference - Final.(Broadcast transcript)

JENNY YANG, ANALYST, UBS: Good morning, everybody. Welcome to the 2008 UBS Global Life Science Conference. My name is Jenny Yang and I'm happy to be your host this morning. At this time, I'd like to welcome Mr. Jason Cigarran, representing Eclipsys. I also would like to remind you there is a breakout session immediately following this presentation in the Juilliard Room downstairs. So right now, please give a warm welcome to Mr. Jason Cigarran.

JASON CIGARRAN, DIRECTOR, IR, ECLIPSYS CORP.: Thank you very much. My name is Jason. I am the director of investor relations for Eclipsys. This is our disclosure statements. So today, I'm going to talk a little bit generally about Eclipsys, then talk about the markets that we're addressing, sort of what is our market opportunity within the healthcare information technology market, go over some of our recent financial results, and then there will be a Q&A downstairs in the Juilliard Room.

So a little bit about Eclipsys. We are one of a handful of enterprise HIT solution providers, which means that we address the majority of the major financial, clinical, and operational workflows within the hospital. We currently -- our headquarters has recently moved to Atlanta, Georgia. We also have a significant presence in India, with well north of 500 employees there. We have a small presence as well in the Middle East in Dubai, and then in Asia, in Singapore.

So a little bit about one of the strongest assets that Eclipsys has is our client base. I'll get into that into more detail later, but it really includes some of the most significant brand-name hospitals in the country, including Johns Hopkins, University of Pennsylvania, as well as multiple entities right here in New York City, such as New York Presbyterian, NYU Medical Center, Bronx Lebanon Hospital, and Memorial Sloan-Kettering.

So what sets Eclipsys apart from the competition? The major differentiator for Eclipsys is that we are the clear leader in clinical adoption for computerized physician order entry, which is where doctors are using the computer to place orders at the point of care through the computer. We also have a modern architecture. We've invested approximately $1 billion in the Microsoft.net architecture, which is a distinguishing point among many of our competitors who have more archaic -- or their solutions are built on more archaic platforms. And then, we call ourselves the outcomes company because we have a proven outcomes methodology that we feel, once we not only get our clients live, but once they're live, help them use the systems to show how they have made demonstrable outcome improvements.

So a little bit more about our client base. We cover most areas within the healthcare. We have integrated delivery networks, many of the leading academic medical centers, as well as moving down into the community hospital, which is one of the strongest growing market segments today.

One of our specialties is we're particularly good at selling and implementing solutions into very specialty care providers, such as cancer settings as well as pediatric facilities. Because those types of organizations require very complex ordering -- a very complex medication procedures given both cancer, the complexity associated with chemotherapy, as well as in the pediatric unit, associated with providing different children based on their weight and size the medications you would provide. And so, one thing our client base gives us is -- Johns Hopkins, the Boston Medical Center -- is when we're moving down market, those community hospitals really want to see how they can leverage what Johns Hopkins has done, what Boston Medical Center has done, and bring those best practices we have established at those organizations and bring them down to their organization. It's also the key factor to help us grow internationally.

So as I said, Eclipsys is the key -- is the leader in clinical adoption for CPOE, and there is an axiom in this industry that if you can't get the doctors to actually use the software, then there's really no point in implementing it. So that's a …